« Back
Home /
Ponsegromab

Ponsegromab

Item no.	HY-P99241-5mg
Manufacturer	MedChem Express
CASRN	2368950-15-4
Amount	5 mg
Quantity options	10 mg 1 ea 1 mg 25 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitor
Specific against	other
Purity	99.41
Dry ice	Yes
Citations	[1]E.J. Roeland, et al. 1696TiP Phase Ib study to assess the effect of PF-06946860 on appetite following subcutaneous administration in patients with anorexia and advanced cancer. VOLUME 32, SUPPLEMENT 5, S1185, SEPTEMBER 01, 2021. Annals of oncology. \|[2]Groarke JD, et al. Ponsegromab for the Treatment of Cancer Cachexia. N Engl J Med. 2024 Dec 19;391(24):2291-2303.
Smiles	[Ponsegromab]
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	PF 06946860
Shipping Condition	Dry ice
Available
Manufacturer - Type	Inhibitory Antibodies
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	TGF-beta/Smad
Shipping Temperature	Dry Ice
Storage Conditions	Store at -80°C for 2 years
Molecular Weight	(145.5 kDa)
Product Description	Ponsegromab (PF 06946860) is a potent and selective humanized anti-GDF15 monoclonal antibody with anti-cachexia activity. Ponsegromab binds to GDF15 and prevents the binding of GDF15 to GFRAL, thereby blocking GDF15/GFRAL-mediated signaling. Ponsegromab can be used in the research of cancers[1][2].
Manufacturer - Research Area	Cancer
Solubility	10 mM in DMSO
Manufacturer - Pathway	Stem Cell/Wnt; TGF-beta/Smad
Clinical information	Phase 3

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-P99241-5mg-safety-datasheet.pdf